Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. - Motzer, R.J.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A.B.; Bourlon, M.T.; Shah, A.Y.; Porta, C.; Suárez, C.; Barrios, C.H.; Richardet, M.; Gurney, H.; et al. (Annals of Oncology, 2026)